An AFFIRM Assay for Potential Biomarkers in Relapsed Breast Cancer
Relapsed or recurrent breast cancer is the chief cause of breast cancer related deaths and it is estimated that one-third of breast cancer patients would likely suffer a relapse. Due to high mortality and incidence, recurrent breast cancer requires better means of prediction, prevention and treatment. The AFFIRM platform uses recombinant antibody technology and selected reaction monitoring (SRM) m
